3176 results for «382»

Filter By

3176 results

TAVI: nightmare in the cathlab - Cardiac arrest, aortic root rupture & duct occluder

16 Nov 2025 – From PCR London Valves 2025

Explore critical complications encountered during TAVI procedures in this session, which highlights urgent scenarios such as cardiac arrest from calcific leaflet shift, aortic root rupture, and embolisation events. It also covers salvage techniques like TAVR-in-TAVR-in-SAVR in cardiogenic shock and management of acute left main occlusion with...

TAVI: nightmare in the cathlab - Cardiac arrest, aortic root rupture & duct occluder

Challenging mitral TEER: overcoming access limitations and anatomical challenges

16 Nov 2025 – From PCR London Valves 2025

This session delves into the challenges of mitral transcatheter edge-to-edge repair (TEER), focusing on complex cases such as denied access, patch dehiscence-induced regurgitation, and functional mitral regurgitation due to amyloid cardiomyopathy. It also highlights innovative imaging approaches, including the use of transthoracic echocardiography as a rescue...

Challenging mitral TEER: overcoming access limitations and anatomical challenges

TAVI in 2025: transforming care with the new valvular heart disease guidelines

18 Nov 2025 – From PCR London Valves 2025

This session explores how the 2025 valvular heart disease guidelines are transforming the landscape of TAVI care and clinical decision-making. It highlights the paradigm shift in managing severe aortic stenosis and provides a global perspective on the challenges and strategies for managing an expanding TAVI patient...

TAVI in 2025: transforming care with the new valvular heart disease guidelines

The index valve matters: optimal index TAVI for a lifetime of possibilities

18 Nov 2025 – From PCR London Valves 2025

Discover how thoughtful index valve selection and implantation techniques can shape the long-term management of patients undergoing TAVI. This PCR London Valves 2025 session highlights treatment considerations for low- and intermediate-risk patients, explores how valve choice affects the feasibility of future interventions, and examines strategies to...

The index valve matters: optimal index TAVI for a lifetime of possibilities

Challenging tricuspid TEER

16 Nov 2025 – From PCR London Valves 2025

This session focuses on the intricacies of transcatheter tricuspid edge-to-edge repair (TEER) addressing iatrogenic tricuspid regurgitation, failed surgical valve repair, and approaches for patients unsuitable for valve replacement. It also examines the management of multiple clip detachments and the procedural nuances required to navigate complex tricuspid...

The next frontier in LAA closure: innovations and opportunities

17 Nov 2025 – From PCR London Valves 2025

Explore the forefront of left atrial appendage (LAA) closure with this session focusing on the latest innovations and clinical opportunities. Topics include recent data on WATCHMAN FLX PRO and VersaCross Connect systems, workflow strategies to improve procedural efficiency, and discussions on upcoming clinical trials such as...

The next frontier in LAA closure: innovations and opportunities

Complex combined interventions

16 Nov 2025 – From PCR London Valves 2025

This session presents complex combined interventions tackling multiple valvular and structural heart challenges simultaneously. It highlights innovative procedural approaches such as the 'super combo' techniques, strategies for managing deteriorative mitral regurgitation post-tricuspid valve replacement, and comprehensive management of torrential tricuspid regurgitation within rheumatic multivalvular disease contexts,...

Hotline - Valvular and structural interventions

16 Nov 2025 – From PCR London Valves 2025

This session presents pivotal advances in valvular and structural heart interventions, covering the SMART-MV trial on mitral valvotomy safety, outcomes of TAVR patients with tricuspid regurgitation undergoing TEER, and the application of the FLOWer embolic protection system across structural heart procedures. Additionally, it explores the impact...

Valve selection in urgent TAVI: evidence from small annulus studies - Hotline

16 Nov 2025 – From PCR London Valves 2025

This session presents cutting-edge research comparing self-expanding and balloon-expandable valves in urgent and emergent TAVI settings, with a focus on small aortic annuli. It includes data from the NAVULTRA and LANDMARK trials, featuring novel biomimetic balloon-expandable valves and early feasibility studies that shed light on valve...

Hotline - TAVI - Part 2

Hotline - Mitral and tricuspid valvular interventions

16 Nov 2025 – From PCR London Valves 2025

This session delves into innovative mitral and tricuspid valvular interventions, highlighting outcomes with the PASCAL precision system and advances in combined MitraClip and TriClip repairs. It discusses predictors of heart failure hospitalization post-transcatheter tricuspid valve repair (TTVR), coronary CT-based pacemaker implantation prediction, and novel devices aimed...

TAVI: high coronary risk - Part 2

16 Nov 2025 – From PCR London Valves 2025

This session presents advanced strategies to mitigate high coronary risk during valve-in-valve TAVR procedures, including the LLAMACORN technique and chimney stenting to prevent coronary obstruction. It discusses management of misaligned prostheses, complex aortic and coronary anatomies, and innovative approaches such as stent crush techniques to ensure...

OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease

04 Nov 2021

Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
OPTIMUM: Early Outcomes From a Prospective Registry of PCI in Patients at Prohibitive Risk for CABG

POPular PAUSE TAVI - Continuation or interruption of oral anticoagulation during TAVI?

02 Sep 2024

Luis Ortega-Paz provides his take on the POPular PAUSE TAVI trial presented by Dirk Jan van Ginkel at the ESC Congress 2024 in London.

Luis Ortega-Paz

Author

Luis Ortega-Paz
POPular PAUSE TAVI

Best of #AHA21 Scientific Sessions: coronary and valvular heart disease trials

14 Nov 2021

Vijay Kunadian provides summaries of study designs and findings in Interventional Cardiology released at the 2021 virtual edition of the American Heart Association Congress. View an infographic of the AVATAR late-breaking trial by Ali Nazmi Calik.

Vijay Kunadian

Author

Vijay Kunadian
Best of #AHA21 Scientific sessions

ESC/EACTS Valvular Heart Disease Guidelines 2021: updates from the 2017 Guidelines

29 Aug 2021

There has been significant expansion in the field of structural heart diseases in the last couple of years, generating an extensive body of evidence and warranting an update to the 2017 Guidelines. Mirvat Alasnag provides an analysis of the updates included in this new document - a joint...

Dr. Mirvat Alasnag

Author

Mirvat Alasnag

Early intervention in patients with asymptomatic severe aortic stenosis and left ventricular myocardial fibrosis (EVOLVED)

30 Oct 2024

Ali Nazmi Calik provides his take on the EVOLVED trial presented by Marc Dweck at TCT 2024 in Washington.

Author

Ali Nazmi Calik
Early intervention in patients with asymptomatic severe aortic stenosis and left ventricular myocardial fibrosis (EVOLVED)
Didn’t find what you were looking for?